Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of In-Situ Autologous Vaccination With Intratumoral and Systemic Hiltonol® (Poly-ICLC) Administered to Prostate Cancer Patients on Active Surveillance

NCT06343077 is registered in ClinicalTrials.gov with Ashutosh Kumar Tewari as lead sponsor.

NCT NCT06343077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06343077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of In-Situ Autologous Vaccination With Intratumoral and Systemic Hiltonol® (Poly-ICLC) Administered to Prostate Cancer Patients on Active Surveillance
Lead sponsor
Ashutosh Kumar Tewari
Phase
Phase 2
Overall status
Recruiting
Start date
January 16, 2024
Completion date
December 31, 2026
Enrollment
114 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer patients on active surveillance